Marcos de Lima
YOU?
Author Swipe
View article: CD34 selected stem cell boost provides robust outcomes in patients with poor graft function
CD34 selected stem cell boost provides robust outcomes in patients with poor graft function Open
Background: Allogenic stem cell transplantation (SCT) is a curative option in several hematological malignancies. However, patients that have poor graft function (PGF) have increased non-relapse mortality as therapeutic options for PGF are…
View article: Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell Transplantation
Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell Transplantation Open
Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been associated with serious cardiotoxicity, including atrial fibrillation (AF) and other cardiac events. In preclinical models, posttransplant clonal hematopoies…
View article: Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma
Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma Open
Summary Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T‐cell (CAR‐T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CA…
View article: Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies Open
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphomas and multiple myeloma (MM). While data pertaining to the efficac…
View article: Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial Open
This clinical trial was funded through University Hospitals Seidman Cancer Center and Washington University School of Medicine Institutional Funds. Correlative analyses were funded in part by the European Union-Next Generation EU-NRRP M6C2…
View article: Two‐Step Estimation Strategy for Predicting Petroleum Reservoir Simulation Jobs Runtime on an HPC Cluster
Two‐Step Estimation Strategy for Predicting Petroleum Reservoir Simulation Jobs Runtime on an HPC Cluster Open
Modeling petroleum field behavior provides crucial knowledge for risk quantification regarding extraction prospects. Since their processing requires significant computational and storage capabilities, oil companies run reservoir simulation…
View article: Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic Leukemia
Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic Leukemia Open
non presente
View article: Water-Path Game
Water-Path Game Open
This study investigates the effectiveness of educational games in the learning process of elementary school students, focusing on raising awareness about water conservation. The "Water-Path Game" was applied to 40 public school students ag…
View article: MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Open
Introduction: In allogeneic hematopoietic cell transplantation (allo-HCT), relapse is one of the major causes of mortality, morbidity, and quality of life impairment. There is an unmet medical need for novel therapies to mitigate this risk…
View article: <i>GATA2</i>-Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation
<i>GATA2</i>-Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation Open
Introduction: GATA2 mutations are acquired in acute myeloid leukemia (AML) and are associated with autosomal dominant forms of AML and myelodysplastic syndromes (MDS), as well as predisposition to human papillomavirus (HPV), nontuberculous…
View article: Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Open
Background: The cornerstone of ICANS pathogenesis is endothelial dysfunction leading to blood-brain barrier disruption driven by inflammatory cytokines. Endothelial dysfunction is often associated with complement activation as in post-tran…
View article: Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma
Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Open
CD19 CAR-T therapy has markedly improved outcomes for Non-Hodgkin's Lymphoma (NHL) patients, yet its availability is critically limited. Around 75-80% of eligible patients in the U.S., and many more globally, do not receive it. Major barri…
View article: A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation
A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation Open
Introduction Alkylating agents such as thiotepa have shown to improve progression-free survival when added to reduced intensity conditioning (RIC) for patients with hematological malignancies undergoing allogeneic hematopoietic stem cell t…
View article: Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis Open
Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) can aff…
View article: Editorial: Efficacy and safety of CAR-T cell therapy in hematologic malignancies
Editorial: Efficacy and safety of CAR-T cell therapy in hematologic malignancies Open
Citation: de Lima M, Di Rocco A and Ribera J-M (2024) Editorial: Efficacy and safety of CAR-T cell therapy in hematologic malignancies. Front. Oncol. 14:1472463. doi: 10.3389/fonc.2024.1472463
View article: Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma Open
Background The short-term complications from chimeric antigen receptor T-cell therapy (CART) are well characterized, but the long-term complications still need to be further investigated. Therefore, herein, we will review the currently ava…
View article: Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma Open
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Robust biomarkers and a complete understanding of CAR T-cell function in the postinfusion phase remain l…
View article: SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program
SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program Open
Chimeric antigen receptor T-cell (CAR-T) therapy has significantly impacted treatment algorithms and clinical outcomes for a variety of patients with hematologic malignancies over the past decade. The field of cellular immunotherapy is cur…
View article: A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia Open
The curative potential of allogeneic hematopoietic transplantation (allo-HCT) in patients with acute lymphoblastic leukemia (ALL) is hampered by relapse. Inotuzumab ozogamicin (INO) is an anti-CD22 monoclonal antibody bound to calicheamici…
View article: Agility and Resilience of the French “Industrie du Futur” During the Covid-19 Pandemic: Insights from a Multi-dimensional Framework
Agility and Resilience of the French “Industrie du Futur” During the Covid-19 Pandemic: Insights from a Multi-dimensional Framework Open
International audience
View article: Editorial: Rising stars in hematology: 2022
Editorial: Rising stars in hematology: 2022 Open
EDITORIAL article Front. Med., 22 November 2023Sec. Hematology Volume 10 - 2023 | https://doi.org/10.3389/fmed.2023.1334125
View article: Measurable Residual <i>FLT3-ITD</i> before Allogeneic Transplant for Acute Myeloid Leukemia
Measurable Residual <i>FLT3-ITD</i> before Allogeneic Transplant for Acute Myeloid Leukemia Open
Background: In the past year, multiple studies have demonstrated the drastically increased risk of relapse and death in patients with Acute Myeloid Leukemia (AML) who have persistent FLT3 internal tandem duplication (ITD) mutations detecta…
View article: Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid Leukemia
Measurable Residual <i>IDH1</i> before Allogeneic Transplant for Acute Myeloid Leukemia Open
Introduction: Detection of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplant (alloHCT) in patients with acute myeloid leukemia (AML) in remission is associated with increased relapse and inferior survival …
View article: OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION
OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION Open
Objectives: Inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate indicated for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL), is associated with hepatotoxicity and hepatic veno-occlusive dise…